Plus   Neg

Stock Alert: Vapotherm Spikes 13%

Shares of medical devices company Vapotherm, Inc. (VAPO) are climbing more than 13% Thursday morning. There are no company-specific news to drive the stock up.

The company's Precision Flow system that uses its proprietary Hi-VNI technology is a mask-free noninvasive ventilatory support for relieving respiratory distress. Vapotherm is seeing a surge in demand for its Precision Flow system during the Covid-19 outbreak.

On April 13, the company had reported preliminary first quarter revenue of approximately $18.9 million, 54% increase from last year, driven by increased demand for Precision Flow systems and single use disposables in Europe and the U.S. On average 4 analysts polled by Thomson Reuters have a consensus revenue estimate of $18.9 million.

Vapotherm is scheduled to report first quarter results on May 5.

VAPO is currently trading at $20.38. It has traded in the range of $6.86- $24.63 in the past 52-weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT